This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cice, G. Articles by Calabrò, R. Search for Related Content PubMed PubMed Citation Articles by Cice, G. Articles by Calabrò, R.

Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy

A prospective, placebo-controlled trial

Gennaro Cice, MD^*,*, Luigi Ferrara, MD^*, Antonello D’Andrea, MD^*, Salvatore D’Isa, MD^*, Attilio Di Benedetto, MD, Antonio Cittadini, MD, Pina Elvira Russo, MD^*, Paolo Golino, MD, PhD^* and Raffaele Calabrò, MD^*

^* Division of Cardiology, Second University of Naples, Naples, Italy
Fresenius Medical Care-Italia, Naples-NephroCare Group, Naples, Italy
Department of Internal Medicine, University Federico II, Naples, Italy

View larger version (14K): [in a new window]   Figure 1 Kaplan-Meyer curves for all-cause mortality during 24-month follow-up cumulative survival rate according to use of carvedilol. Solid lines = carvedilol group; dashed lines = placebo group.

View larger version (13K): [in a new window]   Figure 2 Kaplan-Meyer curves for cardiovascular death (left) and for all-cause hospital admission (right) during 24-month follow-up cumulative survival rate according to use of carvedilol. Solid lines = carvedilol group; dashed lines = placebo group.